ARMP - Earnings call transcript Q1 2018 | Armata Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the AmpliPhi Biosciences Corporation First Quarter 2018 Business Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there’ll be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to the Manager of Business Development, Mr. Dansey. Matt ahead. go Please

Matt Dansey

Good results welcome Matt conference at Development Phil. quarter Dansey, our XXXX Manager Biosciences. financial call. AmpliPhi afternoon you, to and first Business Thank This is

Chief me Executive Operating Joining Igor our Steve and Financial Bilinsky; call today’s are Officer, Officer, Grint; our on Paul Chief Officer, Martin. Chief AmpliPhi’s

Litigation we the the quarter to making anticipated Commission. be Securities result and Actual Securities statements call, XX-Q number These statements Act the and risks of forward-looking. of the considered Harbor in Reform are described to results of our for today’s involve and risks including the of risks All ended our are During could those XXXX, pursuant the XX, XXXX. as related from will be timing made Safe differ materially provisions Form statements and a current these a with may and uncertainties forward-looking business March events upon in based Exchange uncertainties filed of forward-looking such uncertainties. as that expectations Private statements and AmpliPhi’s

now that, would reflect information by Grint. circumstances required I update to publicly to that call. You as are they law, our XX, the place cautioned AmpliPhi this on call disclaims events over made. these reliance accurate by Except of call XXXX. or to were discussed the With AmpliPhi Paul after to revise of Furthermore, information any time turn as any speak which is not forward-looking or statements, May CEO, obligation occur the on as to this only like undue today,

Paul Grint

Today, reporting first XXXX. joining has progress afternoon, us the Good everyone, you made Matt. and in on the for call. we’re Thanks, the quarter AmpliPhi thank

development top Westmead with or under and During we patients Hospital a with with and Sydney of completed announced collaborative Veterans expanded treated initial positive agreement the the two AB-SAXX a successful Affairs, seven cooperative Department ongoing access research AB-PAXX signed agreement U.S. financings. line results program; the the for in period,

the body addition, candidates. of and believe or In conferences. activity on this major Igor cases have the supports more Detailed we preliminary at will drug bacteriophage continued we presented access expanded be that in evidence now build are our of expand later will medical the and to safety say accounts to of call.

to as discuss with we initiate to candidates the to meeting regulatory ahead, the the more Looking for or study FDA or mid-XXXX continue clinical us for quarter one target in potential path fourth XXXX. to early registrational the forward Phase as a our approval of with therapeutic the X

on the positive Before our me remind we announced update you you recent Xrd. on we that January the activity, let data of

AB-PAXX investigational products a January, results as or six success able life-threatening AmpliPhi’s treatment background, seven the receive with we allows As treatment for both these endocarditis Pseudomonas in Both lives. success or and of for occurs in treatment unresponsive seven first IND the with all inhale attempt expanded under antibiotic only with death choice infections patient surgery access interim of patients patients Staphylococcus antibiotic In best save improvement AB-PAXX, the revealed baseline to The was intravenous treatment-related due for death, therapy. we suffered patients by or infections, to available and treating first events from of all Participating and bacteriophage ill therapy. bacteriophage patients were aureus an over patients infections, for patients defined AB-SAXX lung doses in be and intravenously recorded infections three emergency serious unrelated program of and with three the significant in for failure intravenously seven under scheme. treated, available days patients, infections. that When physician patients treatment. and resolution with severely access aeruginosa two patients in an Such determined line signs treating emergency was inhalation. special occurred of determined therapies well-tolerated to and in the out physician’s was to administered One therapy. after Australia to complete investigational during ongoing administered Of are serious access bacteremia, administered were an also in be with symptoms. in treatment XX%. four treatment under the together announce no expanded adverse XXX Furthermore, AB-SAXX treatment treatment to cases to U.S. which top received bacteriophage administered the life-threatening

Importantly, care of for bacteriophage critical XX%. rate initiation patients APACHE of therapy, based seven to predictive system for this validated the on mortality was scoring group prior patient X mortality, predicted scores, the a

present we to Development continue were treat signed phage recently help awarded we Affairs Public Stanford treatments studies us year Infectious As researchers our Mark the University, of of Allergy the principal during the Health Veterans multidrug-resistant National Dr. Holodniy, very AB-SAXX. of of And controlled Chief In of when that which we treatment is to accumulating, one towards as designated be promising we expanded covering of AB-PAXX clearly of The provision Department advance AB-SAXX over recently preclinical a of efforts, has believe to to Institute further interventional encouraged grant to discussion of development potential Veterans the that or and of further this for for The I’d including governmental Surveillance a AB-PAXX. such, investigator therapeutics, collaboration. Research Director AB-SAXX. from results, the initial serious like selected these the NIAID our we we treated the randomized furtherance of site of Cooperative To recognize body believe bought Agreement infection. program and Department funds evidence a the Services online be access demonstrate preclinical and bacterial call a Operating conduct lead have support were program, many System Affairs forward of are data been grant patients Therapeutic approach Furthermore, a to in Health serious by problem. another to Professor for that will used our to setting. To with access our now to to at companies plan and Alto investigated AB-SAXX infections and we Officer, agencies, Medicine for FDA Igor the CRADA agents. Veterans more or we With to needs in order adding end, the expanded registration. turn U.S. advance our the and services FDA potential trial to the for under that option developments expand the clinical path to Development Palo Affairs and and this Bilinsky. Care Disease

Igor Bilinsky

you, Good everyone. Thank Paul. afternoon,

program was the candidate a first Diego. experiences at by This believe and have XXXX Heart administration our Lung with AmpliPhi’s AB-PAXX two AB-SAXX intravenous treatment continues that Transplantation recent bacteriophage AB-PAXXtherapeutic Pseudomonas medical targets noted, presented case the reported clinical The and International access at of presentation University of activity supports team investigational body safety administered like and inhaled aeruginosa. Society and Paul and of was California, Annual of the would Meeting. of the the therapeutics. expanded more conferences, at that been highlight to evidence preliminary we our adding clinical As of to I San

the multidrug-resistant emergency from and Food oral of of then inhalation and was AB-PAXX. developed treatment received the session, the who in therapy part both presentation status. the lung of with resolution initially with male, As Pseudomonas recipient of patient clinically to infectious pneumonia the of topics AB-PAXXwas tolerated responded application intravenously of well bacteriophage transplant titled antibiotics. and investigational months. transplant described bacteriophage the the Drug And therapeutics, episodes a Treatment recurrent treatment obtained intravenously patient over and approval a hot course improved drug U.S. lung XX-year-old including administered pneumonia diseases, several conjunction standard recipient, and Administration with was in respiratory case new care AB-PAXX bilateral and with by aeruginosa and

reported at clinical the serious positive UCSD the the the for team lungs. of administered demonstrated at case outcome accepted our in To lung treatment are replicated scheduled and Two was patient, medical AmpliPhi best site recipients. infection that to addition and clinical infection the the June. In intravenously additional transplant AB-PAXXdistributed intravenously of to the and administered first of in case bacteriophage for have in been therapy for conferences the this knowledge, presentations study of

studies the Case bacteriophage details the the weeks. the of with growing bring a antibiotic along are superbugs. attention to announce resistance like coming will against We treatment potential therapeutics these, published abstracts as increasing in when prices

MIT magazine, Bill in just was an Gates And the of website. America the noticed upcoming Infectious the have to and a been and of posted Technology bacteriophage of others. list there’s at top video for Annual XX the number and therapy Medical therapeutics. time, American the discussing Bloomberg of publications first You by AmpliPhi’s animated including be supported are the trending the plenary session publications Society that the there’ll was this YouTube and of of video about Association, A from dedicated these Library Time on Foundation grant may recent videos. Knowledge among the in Journal page bacteriophage IDWeek Conference on Disease bacteriophage Review, weekend, informative Melinda And therapeutics a October,

therapies supporting there’s addition, infections. on and In novel for significant government resistant funding focus

contracts that AB-SAXX the We may are candidates, government therapeutic AB-PAXX. actively and development support and applying grants our for of

studies For its Institute have the certain fund Allergy preclinical development the announced Disease and NIH as discussions. part therapeutic and in of of services. active we of Infectious example, National mentioned, And opportunities as AB-SAXX will we Paul of other that recently conduct part

bacteriophage companies capabilities funding, opportunities therapeutic also are and with partnership to our additional exploring pharmaceutical along bring with development to candidates. larger, commercialization We

to value. as work in Thalmann announced in alternatives with shareholder addition, the Ladenburg continuing are assist we In an December, to maximize to exploring effort Company we strategic in

Now, turn our for a I financial review CFO, over would Martin, like our of Steve? to Steve the results. call to

Steve Martin

share million as XXXX March the announced for operating March XX, our $X.X the fund was cash we to current and sufficient our $X.X our the million in $X.X compared filed proceeds in two months our like press XXXX. we on used financings cash operating XX, This to the would million December operations period. from of Based Net months our some for resources million SEC as ended plans, I of cash XX, March XX, of includes equivalents the Cash provided as existing conducted be XXXX ended Igor. quarter into will with the three XXXX. in Thanks, results the totaled and XXXX. compared quarterly today three $X.X to activities report believe financial in with fourth release. our of figure highlights

the was and there common XX.X XXXX shares and were XX, compared expenses development the to expenses General first were of turn XXXX to quarter a With XXXX. a the in and Paul. of like decrease $X.X XXXX, May other that XXXX million quarter professional quarter stock-based $X.X quarter million. for call of to Research of million decrease first million as fees first to the non-cash $X.X well I’d primarily administrative million related of legal back As $X.X outstanding. as stock in The were the for of compensation. for and decrease first

Paul Grint

you summarize, these for or well-positioned believe We Subject be study as the call lifesaving discussions, To believe bacteriophage that to more Steve. enter to antibiotic-resistant path Phase now open early possible a forward the candidates quarter critically to suffering on to a FDA fourth to you, like of for year. the ill pivotal near-term your our from therapies patients please one Thank discussions to to as questions. into promise could provide for or I hold are With X this infections. would constructive we these treatment assist? would our initiate tremendous Phil, regulatory it with us drug we product.

Operator

you. Wainwright. Joe Thank The Please go HC comes Instructions] from ahead. first Sure. [Operator with question Pantginis

Joe Pantginis

guys. for afternoon. taking the Thanks Good Hey, question.

curious regard was with out seen collaborative regard patients? of with with to any First, Affairs yet Westmead agreements Veterans Sydney. to the new identifying you impact and have

Paul Grint

This you Thank for is afternoon. question. good Joe, the Paul.

medical and still think really couple had both sites, these As two we plan as a are is plan expected and we formulate And of additional both of that. in continue Can’t there I we we much clearly, have our and on expanded patients enroll to and U.S. talked currently we in to we the patients the obviously mean need than limited in the here do well. I But, board good on as Australia. reported We treating bring sites we’ll here. as say access. a is about news planned before, that access. expanded under number to more we

Joe Pantginis

that And certainly new question your plans I’ve that but FDA, this today is and past asked the a about getting is will like type talk say question feedback design? Company’s I of into, the preface you randomized with want so FDA But but with my study, patients, we that’s update of or pending you next you go what about in wish variation regard to numbers important. would might your setting, of registrational a the obviously Obviously saying a question to Phase my to is controlled said, meeting. by list study X indication post have

you just as input. might So, curious list I have, FDA again the am pending to wish

Paul Grint

But demonstrating before, agree of patients the treating with fail, Great talked important. therapies. question, on we existing medical that types Study you the our FDA priority. in is design indications patients access. wish that’s are these unfortunately expanded highlighted the by goal clearly about the is which list. being just supported Clearly, very we’re to is is as need meeting the That of

We approach [ph] the That’s space. in have something a that that the doesn’t to early pathogen-focused with recognize. FDA guidance regard here. days, therapeutic It’s

the important clearly have We we the dialogue demonstrate believe actually it’s very design enables clinical So, of It’s with obviously to run that a have control us want phage. trials. we that them. to effectiveness

are with others to the plan with points that do together So, those we FDA. discuss three key

Joe Pantginis

of you And EAP in population, the or be least that I that if that the you would at correctly targeting, heard of are I you level think that fact the moment. unresponsiveness the patient the still level might be mentioned at disease

shift still assessment? from with an So, standpoint, but plus that fair would from balance antibiotic I standpoint, towards the necessarily I be the being not the ethical control hopefully, it being effective guess antibiotic phage a those guess would the required patients in

Paul Grint

a Yes. very fair That’s assessment.

at care. I It’s -- focused look whether even patients, your sort is unfortunate generally we is -- infections, that overall therapy lives. you best the of a best done, treat mean, you work actually in pathogen compare number against the the limited of their it’s investigative them the save care may only If how standards it approach standards for of or helping

is you’re be we’ll generally So, that the taking. approach right, that

two alternative don’t a before, sensitivity the obviously biofilm to Based with together discussed we’ve are of as restoration therapy. think, regard introduced disruption therapy clinically therapy we’ve as work, there’re look reasons lot we the and I bacteriophage antibiotic the this use patients that antibiotics. on at to preclinical phage of a biology lot by an the you good as well, anecdotally and phage antibiotic of while seen in therapy still on to

Operator

The [Operator Please Instructions] go Investment next from Zacks Bautz David Research. ahead. question with comes

David Bautz

I’m meeting another patient the curious before if providing outcome be with to going on update FDA. you’re

Paul Grint

to David, address Igor one. that maybe I get will

Igor Bilinsky

Thanks, afternoon. David. Good

we able conferences weeks we year. share with in cannot abstracts been So, do the we medical detailed where about we’ll couple as forward patients we’ll presented are to but excited those with Paul will not we meet the some a this of and that the mentioned, forwardly two data fact about FDA published, And have because be to -- them. so planning of the two before be presentations of expect expect details results in to very to but public look we’re yet some have hearing the and

properly. not is but somewhat phage with is excited expanded will a sure time. think and well therapy essential of are as meeting. public. the yet though keep be focusing to FDA the been will from I’m about the amount not we’ve will presented of But another effectiveness chatting which data we’re and we’ll various year possible, before as and the lot of we the substantial I safety important trials, meeting what cumulative these And one the the again, updated the as clinical depend far It forward FDA As most a timing be on it due very the we extent and about in access. will for what updates, provide obtained controlled randomized you on has And of as this path the proving events

focus most continue. second of the be our in will also of while program half expanded this that year, will access the So

David Bautz

do for of all What treating up how end Okay. ultimately treating those or of them? patients, you percentage inquiries essentially is potentially many it of

Steve Martin

difficult answer, a question to That’s David.

give -- not say Let all the me reason of me just it’s them you let why. because

who who disease. As process we’ve in explained, scheme patients the We requests emergency from physicians and IND and Clearly, don’t from bit special potentially really in provide meet little and serious who regulatory it. of hospitals in standpoint. access get is life-threatening or to the requirements those interested [ph] a treating are therapies phage situation the these read the are investigational an account do the trying patients about basis patient are on patients perhaps

So, in decline we that to have the opportunity. situation

we not appropriate So, we get. patient of of look Clearly, with who requests on regulatory and in regard guidelines. a sick is all for their all to serious it’s a situation, those with merits hospital the those judge meeting at all disease

David Bautz

any of these just are to lastly, everyone? using you have a for patients And you type of data from do set dose able get that treating or kind dosing you’re

Paul Grint

It’s Xrd, down. that on we’re the previously dosing described been patients not in scheme. we did consistent So, absolutely January coming release the for but we our

a through think which you level that And on longer the depending of route or generally well. treated weeks in patients as two administration is couple the treatment looking some we’ve of maybe will a I how obviously, day at addition, consistency responds. twice periods, So, see administration patient inhaled we’re intravenous so

these seen -- we’ve answer think yes I think given in to insights in I your antibiotics the on be we’re is for sick in practicality some They’ll But, in also this twice the regimen, the long setting. dosing patient positive getting doable that in is day patients. that a very eminently a question So, if a responses here, frequently not fact more. particularly dosing there’s a

Operator

I the like turn any conference back Grint over to closing remarks. Paul our concludes Okay. for This to question-and-answer would session. CEO,

Paul Grint

you, Thank everyone call. Phil. today’s in participating you for Thank

at Thank everyone. questions, reach to any you a If or Partners you Westwicke. out and have our evening please additional us again have good

Operator

The for Thank now conference presentation. attending today’s concluded. has you

disconnect. now may You

Armata Pharmaceuticals (ARMP) 15 May 182018 Q1 Earnings call transcript